Seres Therapeutics (MCRB) to Release Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is anticipated to release its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Seres Therapeutics to post earnings of $0.05 per share and revenue of $5.8750 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share for the quarter, topping the consensus estimate of ($2.72) by $0.45. On average, analysts expect Seres Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seres Therapeutics Stock Down 5.6%

Shares of MCRB stock traded down $0.85 during trading hours on Tuesday, hitting $14.39. 60,986 shares of the company were exchanged, compared to its average volume of 115,402. The firm has a market cap of $125.88 million, a PE ratio of -1.29 and a beta of 0.19. Seres Therapeutics has a 1 year low of $6.53 and a 1 year high of $24.67. The firm has a fifty day moving average of $18.54 and a 200 day moving average of $13.52.

Institutional Trading of Seres Therapeutics

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares in the last quarter. Invesco Ltd. grew its position in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Seres Therapeutics in the second quarter valued at approximately $1,016,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on MCRB. Canaccord Genuity Group increased their price objective on shares of Seres Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Seres Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $14.33.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.